Telo Genomics Corp (TSE:TELO) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Telo Genomics Corp has expanded its collaboration with Mayo Clinic to enhance the development of its TeloView diagnostic tests for multiple myeloma, aiming to improve patient outcomes and commercialize its innovative technologies. The partnership includes the validation of TeloViewNDMM, a test for predicting the relapse of newly diagnosed multiple myeloma patients, as a Laboratory Developed Test (LDT).
For further insights into TSE:TELO stock, check out TipRanks’ Stock Analysis page.